Burosumab
Burosumab
Burosumab (pronounced byoo-ROH-soo-mab) is a monoclonal antibody used for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). It is marketed under the brand name Crysvita.
Etymology
The name "Burosumab" is derived from the combination of the Latin words "buro" meaning "to cure" and "sumab" meaning "antibody".
Mechanism of Action
Burosumab works by binding to and inhibiting the activity of fibroblast growth factor 23 (FGF23), a hormone that reduces serum levels of phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney.
Usage
Burosumab is used for the treatment of X-linked hypophosphatemia in children and adults, and for the treatment of tumor-induced osteomalacia when surgical tumor removal is not possible or has been unsuccessful.
Side Effects
Common side effects of Burosumab include headache, rash, pain in extremity, hypocalcemia and restless leg syndrome.
Related Terms
- Monoclonal antibody
- X-linked hypophosphatemia
- Tumor-induced osteomalacia
- Fibroblast growth factor 23
- Phosphorus
- Vitamin D
- Headache
- Rash
- Pain in extremity
- Hypocalcemia
- Restless leg syndrome
External links
- Medical encyclopedia article on Burosumab
- Wikipedia's article - Burosumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski